More tools:Markets·Screener·Research·Chat

AYTU BioPharma, Inc. Common Stock (AYTU) Financial Statements

AYTU BioPharma, Inc. Common Stock
SIC 2834 · PHARMACEUTICAL PREPARATIONS
FIGI BBG001T21Q11
XNAS · usd
2.12▼ 0.07 (-3.20%)
As of 2026-09-09
Valuation
Market Cap
Enterprise Value
Trailing P/E—
Price / Sales
EV / Revenue
EV / EBITDA
Financial Highlights
Revenue (TTM)
Net Income (TTM)
EBITDA
Diluted EPS (TTM)
EBITDA Margin
Net Debt
Trading Information
Previous Close2.19
Day's Range2.12 – 2.24
52-Week Range1.65 – 3.07
Volume14.5K
Avg Volume28.2K
Share Statistics
Shares Outstanding
Employees83
ExchangeXNAS
Listed2008-02-15
Share count as of April 30, 2026
Loading Income Statement…
Key questions about AYTU BioPharma, Inc. Common Stock (AYTU)
What is AYTU BioPharma, Inc. Common Stock's Market Cap?
AYTU BioPharma, Inc. Common Stock's Market Cap is $22.8M, based on as-reported figures from SEC (XBRL) filings.
What is AYTU BioPharma, Inc. Common Stock's Enterprise Value?
AYTU BioPharma, Inc. Common Stock's Enterprise Value is $7.4M, based on as-reported figures from SEC (XBRL) filings.
What is AYTU BioPharma, Inc. Common Stock's Price / Sales?
AYTU BioPharma, Inc. Common Stock's Price / Sales is 0.4×, based on as-reported figures from SEC (XBRL) filings.
What is AYTU BioPharma, Inc. Common Stock's EV / Revenue?
AYTU BioPharma, Inc. Common Stock's EV / Revenue is 0.1×, based on as-reported figures from SEC (XBRL) filings.
What is AYTU BioPharma, Inc. Common Stock's EV / EBITDA?
AYTU BioPharma, Inc. Common Stock's EV / EBITDA is n/m, based on as-reported figures from SEC (XBRL) filings.
What is AYTU BioPharma, Inc. Common Stock's Revenue (TTM)?
AYTU BioPharma, Inc. Common Stock's Revenue (TTM) is $56.6M, based on as-reported figures from SEC (XBRL) filings.
What is AYTU BioPharma, Inc. Common Stock's Net Income (TTM)?
AYTU BioPharma, Inc. Common Stock's Net Income (TTM) is -$34.1M, based on as-reported figures from SEC (XBRL) filings.
What is AYTU BioPharma, Inc. Common Stock's EBITDA?
AYTU BioPharma, Inc. Common Stock's EBITDA is -$12.4M, based on as-reported figures from SEC (XBRL) filings.
What is AYTU BioPharma, Inc. Common Stock's Diluted EPS (TTM)?
AYTU BioPharma, Inc. Common Stock's Diluted EPS (TTM) is -3.17, based on as-reported figures from SEC (XBRL) filings.
What is AYTU BioPharma, Inc. Common Stock's EBITDA Margin?
AYTU BioPharma, Inc. Common Stock's EBITDA Margin is -21.9%, based on as-reported figures from SEC (XBRL) filings.
Showing the most recent year. Subscribe for full statement history.
Income Statement(in thousands of USD, except per-share data)
Source: Akyla.ai
Line ItemMar 31, 2026Dec 31, 2025Sep 30, 2025Jun 30, 2025Mar 31, 2025Dec 31, 2024Sep 30, 2024Jun 30, 2024Mar 31, 2024Dec 31, 2023Sep 30, 2023Jun 30, 2023Mar 31, 2023Dec 31, 2022Sep 30, 2022Jun 30, 2022
Net revenue
YoY growth-32.7%-6.5%-16.2%+3.7%
Cost of goods sold
Gross profit
% of revenue61.2%63.5%66.1%67.8%
Operating expenses:
Selling and marketing
General and administrative
Research and development
Amortization of intangible assets
Restructuring costs
Total operating expenses
% of revenue94.0%76.5%77.0%118.1%
(Loss) income from operations
% of revenue-32.7%-13.0%-10.8%-50.4%
Other income, net
Interest expense
Derivative warrant liabilities (loss) gain
(Loss) income from continuing operations before income tax expense
Income tax (expense) benefit
Net (loss) income from continuing operations
Net income from discontinued operations, net of tax
Net (loss) income
% of revenue-45.3%-69.8%14.1%-130.9%
Basic - net (loss) income (in dollars per share)
Diluted - net (loss) income (in dollars per share)—